Venetoclax Combined with Pediatric-Inspired Chemotherapy Enhances Outcomes in Adolescents and Adults with Ph-Negative Acute Lymphoblastic Leukemia

Highlight

This prospective phase 2 study reveals that integrating the BCL-2 inhibitor venetoclax into pediatric-inspired chemotherapy in adolescents and adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL) considerably improves measurable residual disease (MRD) negativity rates and promotes superior survival outcomes compared to historical controls, without adding significant toxicity.

Specialty calculators

Browse calculators

For clinical reference; use professional judgment.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply